Entera Bio (ENTX) Competitors $1.24 0.00 (0.00%) Closing price 05/22/2026 04:00 PM EasternExtended Trading$1.24 0.00 (-0.40%) As of 05/22/2026 06:06 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock ENTX vs. AKBA, EDIT, ALEC, CNTN, and CHRSShould you buy Entera Bio stock or one of its competitors? MarketBeat compares Entera Bio with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Entera Bio include Akebia Therapeutics (AKBA), Editas Medicine (EDIT), Alector (ALEC), Hillstream Biopharma (CNTN), and Coherus Oncology (CHRS). These companies are all part of the "pharmaceutical products" industry. ENTX vs. AKBAENTX vs. EDITENTX vs. ALECENTX vs. CNTNENTX vs. CHRSHow does Entera Bio compare to Akebia Therapeutics?Akebia Therapeutics (NASDAQ:AKBA) and Entera Bio (NASDAQ:ENTX) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their valuation, profitability, dividends, media sentiment, risk, institutional ownership, earnings and analyst recommendations. Do institutionals and insiders have more ownership in AKBA or ENTX? 33.9% of Akebia Therapeutics shares are owned by institutional investors. Comparatively, 14.1% of Entera Bio shares are owned by institutional investors. 4.3% of Akebia Therapeutics shares are owned by company insiders. Comparatively, 10.4% of Entera Bio shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth. Does the media prefer AKBA or ENTX? In the previous week, Akebia Therapeutics had 1 more articles in the media than Entera Bio. MarketBeat recorded 1 mentions for Akebia Therapeutics and 0 mentions for Entera Bio. Akebia Therapeutics' average media sentiment score of 0.37 beat Entera Bio's score of 0.00 indicating that Akebia Therapeutics is being referred to more favorably in the media. Company Overall Sentiment Akebia Therapeutics Neutral Entera Bio Neutral Which has more volatility & risk, AKBA or ENTX? Akebia Therapeutics has a beta of 0.35, meaning that its share price is 65% less volatile than the broader market. Comparatively, Entera Bio has a beta of 1.54, meaning that its share price is 54% more volatile than the broader market. Do analysts rate AKBA or ENTX? Akebia Therapeutics currently has a consensus target price of $4.67, suggesting a potential upside of 357.52%. Entera Bio has a consensus target price of $9.00, suggesting a potential upside of 625.81%. Given Entera Bio's higher possible upside, analysts clearly believe Entera Bio is more favorable than Akebia Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Akebia Therapeutics 2 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.20Entera Bio 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Is AKBA or ENTX more profitable? Entera Bio has a net margin of 0.00% compared to Akebia Therapeutics' net margin of -8.83%. Akebia Therapeutics' return on equity of -62.72% beat Entera Bio's return on equity.Company Net Margins Return on Equity Return on Assets Akebia Therapeutics-8.83% -62.72% -5.66% Entera Bio N/A -83.31%-70.83% Which has better earnings and valuation, AKBA or ENTX? Akebia Therapeutics has higher revenue and earnings than Entera Bio. Akebia Therapeutics is trading at a lower price-to-earnings ratio than Entera Bio, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAkebia Therapeutics$236.20M1.16-$5.34M-$0.08N/AEntera Bio$40K1,525.82-$11.44M-$0.27N/A SummaryAkebia Therapeutics beats Entera Bio on 10 of the 16 factors compared between the two stocks.How does Entera Bio compare to Editas Medicine?Entera Bio (NASDAQ:ENTX) and Editas Medicine (NASDAQ:EDIT) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their media sentiment, institutional ownership, profitability, dividends, earnings, analyst recommendations, valuation and risk. Which has more volatility & risk, ENTX or EDIT? Entera Bio has a beta of 1.54, suggesting that its share price is 54% more volatile than the broader market. Comparatively, Editas Medicine has a beta of 2.14, suggesting that its share price is 114% more volatile than the broader market. Does the media favor ENTX or EDIT? In the previous week, Editas Medicine had 1 more articles in the media than Entera Bio. MarketBeat recorded 1 mentions for Editas Medicine and 0 mentions for Entera Bio. Entera Bio's average media sentiment score of 0.00 equaled Editas Medicine'saverage media sentiment score. Company Overall Sentiment Entera Bio Neutral Editas Medicine Neutral Do analysts prefer ENTX or EDIT? Entera Bio presently has a consensus price target of $9.00, indicating a potential upside of 625.81%. Editas Medicine has a consensus price target of $5.40, indicating a potential upside of 95.65%. Given Entera Bio's higher possible upside, equities research analysts clearly believe Entera Bio is more favorable than Editas Medicine.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Entera Bio 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00Editas Medicine 1 Sell rating(s) 1 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.57 Do insiders & institutionals believe in ENTX or EDIT? 14.1% of Entera Bio shares are owned by institutional investors. Comparatively, 71.9% of Editas Medicine shares are owned by institutional investors. 10.4% of Entera Bio shares are owned by company insiders. Comparatively, 3.1% of Editas Medicine shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth. Is ENTX or EDIT more profitable? Entera Bio has a net margin of 0.00% compared to Editas Medicine's net margin of -281.59%. Entera Bio's return on equity of -83.31% beat Editas Medicine's return on equity.Company Net Margins Return on Equity Return on Assets Entera BioN/A -83.31% -70.83% Editas Medicine -281.59%-677.39%-58.25% Which has stronger earnings & valuation, ENTX or EDIT? Entera Bio has higher earnings, but lower revenue than Editas Medicine. Entera Bio is trading at a lower price-to-earnings ratio than Editas Medicine, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioEntera Bio$40K1,525.82-$11.44M-$0.27N/AEditas Medicine$40.52M6.67-$160.06M-$1.23N/A SummaryEditas Medicine beats Entera Bio on 8 of the 15 factors compared between the two stocks.How does Entera Bio compare to Alector?Alector (NASDAQ:ALEC) and Entera Bio (NASDAQ:ENTX) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, media sentiment, risk, valuation, profitability, earnings, analyst recommendations and institutional ownership. Do institutionals and insiders have more ownership in ALEC or ENTX? 85.8% of Alector shares are owned by institutional investors. Comparatively, 14.1% of Entera Bio shares are owned by institutional investors. 8.3% of Alector shares are owned by company insiders. Comparatively, 10.4% of Entera Bio shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth. Which has more risk and volatility, ALEC or ENTX? Alector has a beta of 0.64, indicating that its stock price is 36% less volatile than the broader market. Comparatively, Entera Bio has a beta of 1.54, indicating that its stock price is 54% more volatile than the broader market. Is ALEC or ENTX more profitable? Entera Bio has a net margin of 0.00% compared to Alector's net margin of -680.83%. Entera Bio's return on equity of -83.31% beat Alector's return on equity.Company Net Margins Return on Equity Return on Assets Alector-680.83% -295.17% -40.95% Entera Bio N/A -83.31%-70.83% Which has preferable earnings and valuation, ALEC or ENTX? Entera Bio has lower revenue, but higher earnings than Alector. Entera Bio is trading at a lower price-to-earnings ratio than Alector, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAlector$21.05M11.66-$142.93M-$1.19N/AEntera Bio$40K1,525.82-$11.44M-$0.27N/A Do analysts prefer ALEC or ENTX? Alector currently has a consensus target price of $3.63, indicating a potential upside of 64.03%. Entera Bio has a consensus target price of $9.00, indicating a potential upside of 625.81%. Given Entera Bio's higher probable upside, analysts plainly believe Entera Bio is more favorable than Alector.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Alector 2 Sell rating(s) 3 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.13Entera Bio 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Does the media prefer ALEC or ENTX? In the previous week, Alector's average media sentiment score of 0.00 equaled Entera Bio'saverage media sentiment score. Company Overall Sentiment Alector Neutral Entera Bio Neutral SummaryEntera Bio beats Alector on 8 of the 14 factors compared between the two stocks.How does Entera Bio compare to Hillstream Biopharma?Hillstream Biopharma (NASDAQ:CNTN) and Entera Bio (NASDAQ:ENTX) are both small-cap pharmaceutical products companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, analyst recommendations, dividends, media sentiment, institutional ownership, earnings, valuation and profitability. Do analysts prefer CNTN or ENTX? Entera Bio has a consensus target price of $9.00, suggesting a potential upside of 625.81%. Given Entera Bio's stronger consensus rating and higher probable upside, analysts plainly believe Entera Bio is more favorable than Hillstream Biopharma.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Hillstream Biopharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00Entera Bio 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Is CNTN or ENTX more profitable? Hillstream Biopharma's return on equity of -31.50% beat Entera Bio's return on equity.Company Net Margins Return on Equity Return on Assets Hillstream BiopharmaN/A -31.50% -24.72% Entera Bio N/A -83.31%-70.83% Which has stronger valuation & earnings, CNTN or ENTX? Entera Bio has higher revenue and earnings than Hillstream Biopharma. Entera Bio is trading at a lower price-to-earnings ratio than Hillstream Biopharma, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioHillstream BiopharmaN/AN/A-$35.92M-$1.15N/AEntera Bio$40K1,525.82-$11.44M-$0.27N/A Does the media prefer CNTN or ENTX? In the previous week, Hillstream Biopharma had 1 more articles in the media than Entera Bio. MarketBeat recorded 1 mentions for Hillstream Biopharma and 0 mentions for Entera Bio. Entera Bio's average media sentiment score of 0.00 beat Hillstream Biopharma's score of -0.36 indicating that Entera Bio is being referred to more favorably in the news media. Company Overall Sentiment Hillstream Biopharma Neutral Entera Bio Neutral Which has more risk & volatility, CNTN or ENTX? Hillstream Biopharma has a beta of 1.44, indicating that its share price is 44% more volatile than the broader market. Comparatively, Entera Bio has a beta of 1.54, indicating that its share price is 54% more volatile than the broader market. Do institutionals & insiders believe in CNTN or ENTX? 1.2% of Hillstream Biopharma shares are held by institutional investors. Comparatively, 14.1% of Entera Bio shares are held by institutional investors. 6.7% of Hillstream Biopharma shares are held by company insiders. Comparatively, 10.4% of Entera Bio shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term. SummaryEntera Bio beats Hillstream Biopharma on 10 of the 14 factors compared between the two stocks.How does Entera Bio compare to Coherus Oncology?Entera Bio (NASDAQ:ENTX) and Coherus Oncology (NASDAQ:CHRS) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, dividends, institutional ownership, valuation, earnings, media sentiment, analyst recommendations and risk. Does the media refer more to ENTX or CHRS? In the previous week, Entera Bio's average media sentiment score of 0.00 equaled Coherus Oncology'saverage media sentiment score. Company Overall Sentiment Entera Bio Neutral Coherus Oncology Neutral Do insiders & institutionals believe in ENTX or CHRS? 14.1% of Entera Bio shares are held by institutional investors. Comparatively, 72.8% of Coherus Oncology shares are held by institutional investors. 10.4% of Entera Bio shares are held by company insiders. Comparatively, 8.1% of Coherus Oncology shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term. Which has more volatility & risk, ENTX or CHRS? Entera Bio has a beta of 1.54, meaning that its share price is 54% more volatile than the broader market. Comparatively, Coherus Oncology has a beta of 1.01, meaning that its share price is 1% more volatile than the broader market. Is ENTX or CHRS more profitable? Coherus Oncology has a net margin of 397.30% compared to Entera Bio's net margin of 0.00%. Entera Bio's return on equity of -83.31% beat Coherus Oncology's return on equity.Company Net Margins Return on Equity Return on Assets Entera BioN/A -83.31% -70.83% Coherus Oncology 397.30%-198.90%-46.65% Do analysts prefer ENTX or CHRS? Entera Bio presently has a consensus price target of $9.00, indicating a potential upside of 625.81%. Coherus Oncology has a consensus price target of $8.67, indicating a potential upside of 438.30%. Given Entera Bio's higher possible upside, equities analysts plainly believe Entera Bio is more favorable than Coherus Oncology.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Entera Bio 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00Coherus Oncology 0 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.75 Which has preferable valuation and earnings, ENTX or CHRS? Coherus Oncology has higher revenue and earnings than Entera Bio. Entera Bio is trading at a lower price-to-earnings ratio than Coherus Oncology, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioEntera Bio$40K1,525.82-$11.44M-$0.27N/ACoherus Oncology$42.17M5.89$168.02M$1.670.96 SummaryCoherus Oncology beats Entera Bio on 9 of the 14 factors compared between the two stocks. Get Entera Bio News Delivered to You Automatically Sign up to receive the latest news and ratings for ENTX and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ENTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ENTX vs. The Competition ExportMetricEntera BioMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$61.04M$3.37B$6.45B$12.34BDividend YieldN/A2.26%2.76%5.28%P/E Ratio-4.5918.7421.2225.65Price / Sales1,525.82323.98553.9286.28Price / CashN/A125.1743.4956.67Price / Book5.647.0910.377.14Net Income-$11.44M$24.45M$3.57B$335.98M7 Day Performance0.81%5.45%6.01%3.56%1 Month Performance10.71%2.43%3.52%2.54%1 Year Performance-36.41%62.98%34.13%35.05% Entera Bio Competitors List ExportCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ENTXEntera Bio2.9364 of 5 stars$1.24flat$9.00+625.8%-36.4%$61.04M$40KN/A20Positive NewsAKBAAkebia Therapeutics2.4503 of 5 stars$0.89-11.6%$4.67+422.6%-64.3%$241.17M$236.20MN/A430High Trading VolumeEDITEditas Medicine2.8508 of 5 stars$2.46-3.0%$5.40+120.0%+78.1%$239.78M$40.52MN/A230Gap DownALECAlector3.1222 of 5 stars$2.12-0.2%$3.63+71.4%+78.2%$237.05M$21.05MN/A270CNTNHillstream Biopharma0.6462 of 5 stars$3.33+2.0%N/AN/A$232.10MN/AN/A2News CoverageGap Down Related Companies and Tools Related Companies Akebia Therapeutics Competitors Editas Medicine Competitors Alector Competitors Hillstream Biopharma Competitors Coherus Oncology Competitors Entrada Therapeutics Competitors Avidity Biosciences Competitors Tonix Pharmaceuticals Competitors Cybin Competitors Fate Therapeutics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ENTX) was last updated on 5/25/2026 by MarketBeat.com Staff. From Our PartnersSpaceX eyes a 1.75 trillion valuation - here's what to knowElon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...Brownstone Research | Sponsored$30 stock to buy before Starlink goes public (WATCH NOW!)In the next 3 minutes… James Altucher – legendary investor and venture capitalist… And someone who’s kno...Paradigm Press | SponsoredYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredMy feud with Zohran MamdaniEmmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...Stansberry Research | SponsoredSpaceX IPO hides a much bigger storyThe SpaceX IPO could be the biggest in history at $1.75 trillion - but the real story isn't the IPO itself. ...Weiss Ratings | SponsoredSpaceX will mint billionaires. You won't be one of them.By the time a company goes public, 95% of profits have already been made. Insiders bought SpaceX at $20 billio...Behind the Markets | SponsoredSatellite Images Spot Potential $10 Trillion Discovery'Dark Energy': Elon Musk's Next Potential $10 Trillion Move A highly secure site in West Texas now houses a...Altimetry | SponsoredHey, it's Jon Najarian. The SpaceX IPO is right around the corner. But I discovered Elon may have something BIGGER planned. Check this out before June 9th...After being invited to the SpaceX launch headquarters in Cape Canaveral from one of Elon's top lobbyists… Hall...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Entera Bio Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share Entera Bio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
